Related Experiment Videos
Is high titre ANA specific for connective tissue disease?
Clinical and Experimental Rheumatology
|August 19, 2000
Summary
A high titre antinuclear antibody (ANA) test is not specific for connective tissue diseases (CTD). Many patients with high-titre ANA results do not have a CTD diagnosis, suggesting higher cutoffs may not improve diagnostic certainty.
Area of Science:
- Immunology
- Rheumatology
- Clinical Diagnostics
Background:
- Antinuclear antibody (ANA) testing is a sensitive but not specific marker for systemic lupus erythematosus and other connective tissue diseases (CTD).
- High-titre ANA results are often interpreted as indicative of CTD, but their diagnostic specificity requires further investigation.
Purpose of the Study:
- To evaluate the diagnostic specificity of high-titre ANA results for connective tissue diseases (CTD).
- To determine if a higher ANA titre cutoff offers improved diagnostic certainty compared to screening titres.
Main Methods:
- Retrospective review of medical records for patients with high-titre ANA (defined as 4 dilutions above screening) over a 6-month period.
- Analysis of diagnoses, specialist consultations, and results of antibodies to extractable nuclear antigens (ENA) and native DNA tests.
Main Results:
- Of 320 reviewed patient records with high-titre ANA, 35% were diagnosed with CTD.
- A significant proportion of patients (29%) had no specific diagnosis recorded, and CTD was not suggested by available data.
- Positive anti-ENA or anti-DNA antibodies were found in 22% and 8% of sera, respectively.
Conclusions:
- A substantial percentage of patients with high-titre ANA lack a CTD diagnosis at the time of testing.
- Increasing the reporting cutoff for ANA may not sufficiently enhance specificity to be a valuable diagnostic tool on its own.